

What is claimed is:

1. A CCI-779 cosolvent concentrate which comprises, CCI-779, a parenterally acceptable solvent, and an antioxidant component.
2. The cosolvent concentrate of claim 1, wherein the parenterally acceptable solvent is dimethylacetamide.
3. The cosolvent concentrate of claim 1, wherein the parenterally acceptable solvent is an alcoholic solvent.
4. The cosolvent concentrate of claim 3, wherein the alcoholic solvent comprises ethanol, propylene glycol, polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 600, or polyethylene glycol 1000.
5. The cosolvent concentrate of claim 1, wherein the antioxidant component comprises citric acid, glycine, d,l- $\alpha$ -tocopherol, BHA, BHT, monothioglycerol, ascorbic acid, or propyl gallate.
6. A CCI-779 cosolvent concentrate which comprises, CCI-779, citric acid, and dehydrated ethanol.
7. A cosolvent concentrate according to claim 1, wherein CCI-779 comprises from about 0.05 mg/mL to about 50 mg/mL.
8. A cosolvent concentrate according to claim 1, wherein CCI-779 comprises from about 25 mg/mL.
9. A cosolvent concentrate according to claim 1, wherein the antioxidant comprises from about 0.001% to 1.0%w/v.
10. A CCI-779 cosolvent concentrate which comprises, CCI-779, dehydrated ethanol, d,l- $\alpha$ -tocopherol, and propylene glycol.

11. The cosolvent concentrate according to claim 10, which further comprises citric acid.
12. A parenteral formulation which comprises CCI-779, an alcoholic solvent, an antioxidant, a diluent solvent, and a surfactant.
13. The formulation according to claim 12, wherein the alcoholic solvent is ethanol, propylene glycol, polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 600, or polyethylene glycol 1000.
14. The formulation according to claim 12, wherein the antioxidant is citric acid, glycine, d,l- $\alpha$ -tocopherol, BHA, BHT, monothioglycerol, ascorbic acid, or propyl gallate.
15. The formulation according to claim 12, wherein the diluent solvent is water, ethanol, polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 600, polyethylene glycol 1000, or propylene glycol.
16. The formulation according to claim 12, wherein the surfactant is polysorbate 20, polysorbate 80, a bile acid, lecithin, an ethoxylated vegetable oil, vitamin E tocopherol propylene glycol succinate, or polyoxyethylene-polyoxypropylene block copolymers.
17. The formulation according to claim 12, wherein CCI-779 comprises from about 1 mg/mL to about 25 mg/mL.
18. The formulation according to claim 12, wherein CCI-779 comprises from about 2.5 mg/mL to about 10 mg/mL.
19. The formulation according to claim 12, wherein the antioxidant comprises from about 0.0005 to 0.5% w/v of the formulation.
20. The formulation according to claim 12, wherein the surfactant comprises from about 0.5% to about 10% w/v of the formulation.

21. The formulation according to claim 12, wherein the solvent comprises from about 10% to about 90% w/v of the formulation.
22. A process for preparing a parenteral CCI-779 formulation which comprises
- (a) mixing CCI-779 with a parenterally acceptable solvent and an antioxidant component to provide a cosolvent concentrate;
  - (b) mixing a diluent solvent and a surfactant to produce a diluent; and
  - (c) mixing the cosolvent concentrate with the diluent to provide the CCI-779 parenteral formulation.
23. The process according to claim 22, wherein the solvent is an alcoholic solvent comprising ethanol, propylene glycol, polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 600 or polyethylene glycol 1000.
24. The process according to claim 22, wherein the antioxidant component comprises citric acid, d,l- $\alpha$ -tocopherol, BHA, BHT, monothioglycerol, ascorbic acid, or propyl gallate.
25. The process according to claim 22, wherein the diluent solvent is water, ethanol, polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 600, polyethylene glycol 1000, or propylene glycol.
26. The process according to claim 22, wherein the surfactant is polysorbate 20, polysorbate 80, a bile acid, lecithin, an ethoxylated vegetable oil, vitamin E tocopherol propylene glycol succinate, or polyoxyethylene-polyoxypropylene block copolymers.
27. The process according to claim 22, wherein the solvent is dehydrated ethanol, the antioxidant is citric acid, the diluent solvents are water and polyethylene glycol 400, and the surfactant is polysorbate 20 or polysorbate 80.
28. The process according to claim 22, wherein the solvent is dehydrated ethanol, the antioxidant is citric acid, the diluent solvents are dehydrated ethanol and polyethylene glycol 400, and the surfactant is polysorbate 20 or polysorbate 80.

29. The process according to claim 22, wherein the solvents are dehydrated ethanol and propylene glycol, the antioxidant is d,l- $\alpha$ -tocopherol, the diluent solvents are water and polyethylene glycol 400, and the surfactant is polysorbate 20 or polysorbate 80.

30. The process according to claim 22, wherein the solvents are dehydrated ethanol and propylene glycol, the antioxidant is d,l- $\alpha$ -tocopherol, the diluent solvents are dehydrated ethanol and polyethylene glycol 400, and the surfactant is polysorbate 20 or polysorbate 80.